Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: Provided are a human IL-15 molecule mutant and a fusion protein containing the IL-15 mutant and combined mutations, wherein the fusion protein can mediate the activation and amplification of immune cells and can be used for treating tumor disease

Abstract: In a particular embodiment, a method of functional safety in a battery management system is disclosed that includes: generating, by a module monitoring system of the battery management system, battery sensor data; generating, by the module monitoring system, based on the battery sensor data, integrity data; sending, by the module monitoring system, via a wireless black communication channel to a wireless network controller of the battery management system, the battery sensor data and the integrity data; and sending, by the wireless network controller, to a vehicle control system, the battery sensor data.

Abstract: In a particular embodiment, functional safety in a battery management system includes a network controller of a battery management system (BMS) receiving from a module monitoring system (MMS) of the BMS, a message that includes a first set of data type blocks. In this embodiment, the network controller determines for the first set of data type blocks, a block sequence order that indicates a position of each data type block within the message. The network controller determines whether the message conforms with a predetermined block sequence protocol. In response to determining that the message does not conform with a predetermined block sequence protocol, the network controller determines that data within the message is stale.

Abstract: Methods, apparatuses, and computer program products for utilizing a multi-functional wireless module monitoring system (MMS) in an electric battery pack are disclosed. In a particular embodiment, utilizing the multi-functional wireless MMS in an electric battery pack includes the multi-functional wireless MMS monitoring one or more attributes of a plurality of battery cells in the electric battery pack and generating based on the monitored one or more attributes, battery sensor data. Responsive to the multi-functional wireless MMS operating in a first operational mode, the multi-functional wireless MMS transmits via a wireless interface, a first set of the battery sensor data to a wireless network controller (WNC) of a battery management system (BMS). Responsive to the multi-functional wireless MMS operating in a second operational mode, the multi-functional wireless MMS transmits via a wired interface, a second set of the battery sensor data.

Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: Methods, apparatuses, systems, and computer program products for lifetime battery tracking using a wireless interface are disclosed. During production and assembly of a battery pack, the location of a battery module in a production line is tracked using detected signal strengths from a wireless transmitter of a battery module monitoring system. During the life of the battery module, the battery module monitoring system provides battery usage data that can be combined with vehicle data for diagnostic analysis.

Abstract: Methods, apparatuses, systems, devices, and non-transitory for resolving a failure in communication within a wireless battery management system (BMS) of a vehicle are disclosed. In a particular embodiment, a wireless network controller (WNC) of a wireless BMS determines that there is a failure in communication between the WNC and one or more module measurement systems (MMS). The WNC also determines a background radio frequency (RF) power level of a communication channel between the WNC and the one or more MMS and based on the determined background RF power level, selects one or more actions to perform in an attempt to correct the failure in communication between the WNC and the one or more MMS. In this particular embodiment, the WNC performs the selected one or more actions in an attempt to correct the failure in communication.

Abstract: A wireless protocol in a sensing system, including: sending, by a wireless network controller (WNC), to a plurality of wireless sensor nodes, based on a time division multiple access (TDMA), a synchronization message; and receiving, by the wireless network controller, based on the TDMA, first sensor data from each wireless sensor node of the plurality of wireless sensor nodes.

Abstract: An antibody or antigen-binding fragment specifically binds to human programmed cell death ligand-1 (PD-L1). The antibody or antigen-binding fragment is able to enhance the function of T cells and upregulate a T cell-mediated immune response. The antibody or the antigen-binding fragment is useful for the treatment of diseases, e.g. tumor, associated with aberrant expression of PD-L1 and/or dysfunction of T cells.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: Provided are biomarkers for predicting the efficacy of BCL-2/BCL-XL dual or selective inhibitors in treating cancer patients. The biomarkers comprise a complex comprising BCL-2 or BCL-XL. Also provided are methods and compositions, e.g., kits, for evaluating levels of the biomarkers and methods of using such levels to predict a cancer patient's response to the BCL-2/BCL-XL dual inhibitors or BCL-XL or BCL-2 inhibitors. Such information can be used in determining prognosis and treatment options for cancer patients.

Abstract: Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.

Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: According to one embodiment, a system for hybrid communication between electronic circuits is disclosed. The system includes a plurality of sensor nodes configured to read data from one or more sensors. The system also includes a master node configured to receive periodic data transmissions from each of the plurality of sensor nodes via a primary transmission medium and a secondary transmission medium, which is different from the primary transmission medium.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.